title: Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia.
abstract: In order to investigate the effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia, 144 white male Wistar rats were randomized into six groups: Groups A and B received saline or moxifloxacin once per day, respectively; Groups C and D received saline or moxifloxacin twice per day, respectively, and Groups E and F received saline or moxifloxacin three times per day, respectively. Blood samples were taken at 6 and 30 hr after administration of S. maltophilia. Malonodialdehyde (MDA), WBC counts, bacterial tissue overgrowth, serum concentrations of moxifloxacin and survival were assessed. Survival analysis proved that treatment with moxifloxacin every 8 hr was accompanied by longer survival than occurred in any other group. Tissue cultures 30 hr after bacterial challenge showed considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals, but not in their livers. At 6 hr there were no statistically significant differences between groups. However, at 30 hr, MDA concentrations were significantly greater (P = 0.044) and WBC counts significantly lower (P = 0.026) in group D than in group C. No statistically significant variations were observed between the other groups. Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as indicated by MDA production and survival prolongation, without being toxic, as indicated by WBC count. Therefore, under the appropriate conditions, moxifloxacin has a place in treatment of infections in immunosuppressed patients and of infections caused by S. maltophilia.
authors.forename: Orestis
authors.initials: O
authors.lastname: Ioannidis
authors.forename: Basilios
authors.initials: B
authors.lastname: Papaziogas
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Tsiaousis
authors.forename: George
authors.initials: G
authors.lastname: Paraskevas
authors.forename: Evangelos J
authors.initials: EJ
authors.lastname: Giamarellos-Bourboulis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Koutelidakis
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000494:pharmacology*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D016867:Immunocompromised Host; D007958:Leukocyte Count; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D000077266:Moxifloxacin; D051381:Rats; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000378:metabolism* / Q000382:microbiology / Q000401:mortality; D020615:Stenotrophomonas maltophilia
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin